180 Life Sciences Corp. (NASDAQ: ATNF) has recently struck a deal with Prof. Avi Domb from Hebrew University’s School of Pharmacy and Prof. Elyad Davidson from Hadassah Hospital to conduct a groundbreaking pharmacokinetic (PK) study on cannabidiol (CBD). The purpose of this research is to measure how much CBD is actually absorbed and stored in the blood of individuals who take the pill orally. This is the first study of its kind and promises to open up new doors to improved treatments.
CBD preparations have previously been approved by the FDA for rare forms of childhood epilepsy, but due to its low and variable uptake following oral delivery, progress in its therapeutic application has been hindered. In order to address this challenge, Professor Domb and his colleagues have developed ProNanoLipospheres (PNL), a mixture of components available over the counter, which form little droplets and have been shown to increase uptake of CBD, decrease absorption variability and enable controlled release.
Human PK studies are now being designed to test whether the formulation truly increases CBD blood levels following oral administration, in a study that will be performed at Hadassah Hospital. Additionally, the legacy of the late Professor Raphael Mechoulam of Hebrew University promises to deliver potential clinical benefits, as his discovery of the human endocannabinoid system led to the development of synthetic CBD compounds with anti-inflammatory and analgesic properties in animal models.
180 Life Sciences is pioneering a new pill formulation of CBD with the potential to revolutionize its absorption and medicinal use. According to co-chairman Prof. Sir Marc Feldman, this innovation may enable the use of CBD and derivatives in multiple conditions such as pain (where safe drugs are in short supply), anxiety, and even weight management. Human trials have already shown that CBD may reduce post-operative pain and even decrease dependence on opioids, a major accomplishment. Prof. Domb’s team is no stranger to formulating medicines for therapeutic value, and we’re excited to see the results of their work.
We are thrilled to be in collaboration with the geniuses of 180 Life Sciences team, including Prof. Marc Feldmann who took the lead in creating antibodies that target Tumor Necrosis Factor (TNF) for rheumatoid arthritis. Our team’s formulation may incorporate purely artificial CBD, which is available for use in numerous countries without a need to abide to controlled substances regulations, thus making it convenient for administration. Prof. Domb of Hebrew University’s School of Pharmacy has expressed immense confidence in this quest of ours.
We are thrilled to be joining forces with renowned cannabis researcher Prof. Domb, as we believe this work could very well be the key to unlocking the full capacity of solid PNL. If the outcomes are positive, this could open up a whole new world of potential therapeutic applications, such as the combination of anti-inflammatory biologics with the pain-reducing capabilities of CBD. We have also recently patented a treatment method for weight management combining CBD and GLP-1 agonists, and the convenience of this potential solid pill formulation could add fuel to that fire.
At the 2022 American Academy of Orthopaedic Surgeons Annual Meeting, Michael J. Alaia, MD, FAAOS will give a talk discussing the effectiveness of an orally absorbed CBD tablet in alleviating postoperative pain after rotator cuff surgery. 180 Life Sciences has filed patents to protect its discoveries, with its current focus being their core assets in the clinic, which includes an anti-TNF program for Dupuytren’s disease and delirium, and a CBD program.
About 180 Life Sciences Corp.
180 Life Sciences Corp. is a clinical stage biotechnology company with a mission to develop novel therapeutics to address unmet medical needs in chronic pain, inflammation and fibrosis. We are putting a particular emphasis on an anti-TNF (tumor necrosis factor) combination therapy program to address a wide range of inflammatory disorders. Our team of experts are committed to pushing the boundaries of science through innovative research. We are enthusiastic about promoting a healthier future and providing quality care for all.
This press release contains forward-looking statements regarding the future of 180 Life Sciences, including but not limited to our ability to commercialize PNL and other drug candidates, the timing of our marketing authorization application (MAA) and new drug application (NDA) submissions to regulatory authorities, the success of our clinical trials to demonstrate safety and efficacy of our products, our ability to come to mutually agreeable terms with third parties, and the timing and costs of required studies and trials.
There is a significant amount of risk and uncertainty associated with these statements, including potential delays in clinical trials, issues raised by regulatory authorities, unexpected adverse side effects or inadequate therapeutic efficacy of the drug candidates, and changes in laws and regulations. As such, readers should not rely on these forward-looking statements as predictions of future events. We cannot guarantee any outcomes, levels of activity, performance or achievements.